|
Palatin Technologies fights the dragons of illness with protein and peptide-based therapies. The biopharmaceutical company is researching and developing potential drugs that target melanocortin (MC) receptors and other peptide receptors in the brain. Such drugs could be used in the treatment of obesity, diabetes, and congestive heart failure. The company's research programs use its MIDAS (Metal Ion-induced Distinctive Array of Structures) technology to design drugs that mimic peptides. Palatin enjoys collaboration agreements with larger drug firms, including AstraZeneca.
|
| | | Contact Information | |
Address: |
4-C Cedar Brook Dr., Cedar Brook Corporate Center
Cranbury, NJ 08512
| | Phone: | 609-495-2200 | | Fax: | 609-495-2201 |
|
| Financial
Highlights | | Fiscal Year End: | June | | Revenue (2009): | 11.40 M | | Revenue Growth (1 yr): | (-1.10%) | | Employees (2009): | 43 | | Employee Growth (1 yr): | (-6.50%) |
|
|
Key People
| | • |
Chairman:
John K. A. Prendergast
| | • |
President, CEO, and Director:
Carl Spana
| | • |
EVP Operations, CFO, Secretary, and Treasurer:
Stephen T. Wills
|
|
|
